237 related articles for article (PubMed ID: 9164315)
1. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
Lancet; 1997 May; 349(9063):1422-8. PubMed ID: 9164315
[TBL] [Abstract][Full Text] [Related]
2. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Tcheng JE; Harrington RA; Kottke-Marchant K; Kleiman NS; Ellis SG; Kereiakes DJ; Mick MJ; Navetta FI; Smith JE; Worley SJ
Circulation; 1995 Apr; 91(8):2151-7. PubMed ID: 7697843
[TBL] [Abstract][Full Text] [Related]
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
EPIC Investigators
N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
Topol EJ; Califf RM; Weisman HF; Ellis SG; Tcheng JE; Worley S; Ivanhoe R; George BS; Fintel D; Weston M
Lancet; 1994 Apr; 343(8902):881-6. PubMed ID: 7908357
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
[TBL] [Abstract][Full Text] [Related]
10. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Harrington RA; Kleiman NS; Kottke-Marchant K; Lincoff AM; Tcheng JE; Sigmon KN; Joseph D; Rios G; Trainor K; Rose D
Am J Cardiol; 1995 Dec; 76(17):1222-7. PubMed ID: 7503000
[TBL] [Abstract][Full Text] [Related]
11. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Mandak JS; Blankenship JC; Gardner LH; Berkowitz SD; Aguirre FV; Sigmon KN; Timmis GC; Gilchrist IC; McIvor M; Resar J; Weiner BH; George BS; Talley JD; Lincoff AM; Tcheng JE; Califf RM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1518-24. PubMed ID: 9626829
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
[TBL] [Abstract][Full Text] [Related]
13. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
Tardiff BE; Califf RM; Tcheng JE; Lincoff AM; Sigmon KN; Harrington RA; Mahaffey KW; Ohman EM; Teirstein PS; Blankenship JC; Kitt MM; Topol EJ
J Am Coll Cardiol; 1999 Jan; 33(1):88-96. PubMed ID: 9935014
[TBL] [Abstract][Full Text] [Related]
15. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Goa KL; Noble S
Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
[TBL] [Abstract][Full Text] [Related]
16. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
[TBL] [Abstract][Full Text] [Related]
17. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
[TBL] [Abstract][Full Text] [Related]
18. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E; Boersma E; Akkerhuis KM; Harrington RA; Lincoff AM; Deckers JW; Karsch K; Kleiman NS; Vahanian A; Topol EJ; Califf RM; Simoons ML
Eur Heart J; 2002 Feb; 23(3):239-46. PubMed ID: 11792139
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Gilchrist IC; O'Shea JC; Kosoglou T; Jennings LK; Lorenz TJ; Kitt MM; Kleiman NS; Talley D; Aguirre F; Davidson C; Runyon J; Tcheng JE
Circulation; 2001 Jul; 104(4):406-11. PubMed ID: 11468201
[TBL] [Abstract][Full Text] [Related]
20. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.
Zeymer U; Zahn R; Schiele R; Jansen W; Girth E; Gitt A; Seidl K; Schröder R; Schneider S; Senges J
Eur Heart J; 2005 Oct; 26(19):1971-7. PubMed ID: 15857851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
